Anurag Singh
Dr. Anurag Singh is an immunologist and mitochondrial longevity scientist. His research focuses on the effects of the postbiotic and mitophagy inducer Urolithin A. His published studies investigate Urolithin A's impact on age-related immune decline, cardiovascular health biomarkers, and athletic performance and recovery.
34 claims checked on air: 2 context 1 contradicted 7 overstated 20 supported 4 unverified 8 flagged
What they said on air
5 citing their own research
Placebo-controlled randomized trials show that supplementation with a bacterial-derived postbiotic yields a 10% to 12% improvement in strength and an approximate 10% improvement in VO2 levels in the absence of exercise or dietary changes.
"Mostly the trials we have run in placebo-controlled randomized trials, we see in the absence of exercise, in the absence of changing their diets, you get about a 10-12% improvement in strength, you get about a 10% improvement in VO2 levels." (said at 0:00:10)
A placebo-controlled randomized trial in middle-aged adults evaluating daily supplementation with Urolithin A (a gut bacterial-derived postbiotic) without concomitant exercise or dietary intervention demonstrated a ~12% increase in muscle strength and significant improvements in aerobic endurance measured as peak oxygen consumption (VO2 peak). While these findings directly support the speaker's statement, certainty is moderate because the evidence comes from limited RCTs in specific populations.
A human brain neuron contains approximately 17,000 mitochondria, and a skeletal muscle cell contains 10,000 to 15,000 mitochondria.
"I think it's like, what is it, 17,000 of these in every brain cell? GUEST1: In every, and close to 10-15,000 in a skeletal muscle cell." (said at 0:08:52)
No published record matching the claim that a human brain cell contains approximately 17,000 mitochondria and a skeletal muscle cell contains 10,000 to 15,000 mitochondria was located; this does not prove the claim false. While neurons and skeletal muscle cells have high metabolic demands and substantial mitochondrial content, mitochondrial morphology exists largely as dynamic reticular networks rather than uniform, discrete counts across cell types.
Mitochondrial DNA leaking into circulation from damaged mitochondria stimulates inflammatory pathways.
"Really, these damaged mitochondria that become leaky, and the damaged mitochondrial DNA—I mean, mitochondria have their own DNA that leaks out into the circulation and causes, you know, inflammation." (said at 0:14:23)
The speaker's statement accurately reflects a well-established biological mechanism. Mitochondria possess their own circular DNA (mtDNA). When mitochondrial integrity is compromised through damage, stress, or cell death, mtDNA can leak into the cytosol, extracellular space, and systemic circulation. Because of its evolutionary similarity to bacterial DNA (such as unmethylated CpG motifs), circulating cell-free mtDNA acts as a damage-associated molecular pattern (DAMP). It is recognized by innate immune sensors including Toll-like receptor 9 (TLR9), the cGAS-STING pathway, and the NLRP3 inflammasome, triggering the production and release of pro-inflammatory cytokines and driving systemic inflammation.
- supports: Circulating Mitochondrial DNA Stimulates Innate Immune Signaling Pathways to Mediate Acute… (Frontiers in immunology 2021) · cited 62x in the literature
"Mitochondrial DNA (mtDNA) released from damaged mitochondria could serve as a danger-associated molecular pattern (DAMP) and activate the innate immune system through STING, TLR9, NLRP3, and some other adaptors, and further mediate tubular cell inflammation and apoptosis." (abstract, passage verified)
pubmedfull study (doi) - supports: Mitochondrial DNA as inflammatory DAMP: a warning of an aging immune system? (Biochemical Society transactions 2023) · cited 50x in the literature
"Mitochondria are an important source of DAMPs, including mitochondrial DNA - the small, circular, double-stranded DNA molecule found in multiple copies in the organelle. mtDNA can be sensed by at least three molecules: the Toll-like receptor 9, the NLRP3 inflammasomes, and the cyclic GMP-AMP synthase (cGAS). All these sensors can lead to the release of proinflammatory cytokines when engaged. The release of mtDNA by damaged or necrotic cells has been observed in several pathological conditions, often aggravating the course of the disease. Several lines of evidence indicate that the impairment of mtDNA quality control and of the organelle homeostasis associated with aging determines an increase in the leakage of mtDNA from the organelle to the cytosol, from the cell to the extracellular space, and into plasma." (abstract, passage verified)
pubmedfull study (doi)
Unbiased gene expression analysis of 30,000 genes in human skeletal muscle biopsies reveals that the top 30 downregulated pathways in fatigued older adults are all mitochondrial-linked.
"you look at the 30,000 genes in the in the skeletal muscle and you ask in an unbiased way, what are the top 30 pathways that are downregulated? They are all mitochondrial-linked." (said at 0:15:25)
Transcriptomic profiling of human skeletal muscle biopsies across aging, pre-frailty, and sarcopenia consistently shows significant downregulation of mitochondrial genes and oxidative phosphorylation pathways. For example, observational microarray analyses comparing pre-frail older adults to active older adults demonstrated marked downregulation of mitochondrial gene expression alongside impaired respiratory complex activity. While bioenergetic and mitochondrial pathways are among the most prominently enriched downregulated sets in aged muscle, transcriptional remodeling in skeletal muscle aging also involves broader processes including proteostasis, inflammatory signaling, and structural components.
Exercise activates the PGC-1alpha pathway to stimulate mitochondrial biogenesis and the production of new mitochondria.
"this is the whole PGC-1alpha pathway where, you know, where you stimulate this mitochondrial biogenesis, you can improve the growth of new mitochondria." (said at 0:17:08)
The speaker's statement accurately describes a foundational principle of exercise physiology and molecular metabolism. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is activated in skeletal muscle by exercise (via upstream energy-sensing pathways like AMPK and SIRT1) and coordinates the downstream transcription of nuclear and mitochondrial genes required for mitochondrial biogenesis and mitochondrial network remodeling.
- supports: PGC-1α-mediated regulation of mitochondrial function and physiological implications. (Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2020) · cited 399x in the literature
"The transcriptional co-activator peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α) has been characterized as a major factor in the transcriptional control of several mitochondrial components. Thus, PGC-1α is often described as a master regulator of mitochondrial biogenesis as well as a central player in regulating the antioxidant defense." (abstract, passage verified)
pubmedfull study (doi) - supports: The Central Role of the AMPK/SIRT1/PGC-1α Signaling Axis in Skeletal Muscle Physiology and… (Pharmaceuticals (Basel, Switzerland) 2026)
"The signaling axis composed of AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) serves as a critical hub that senses cellular energy status, coordinates mitochondrial biogenesis, regulates muscle fiber type switching, and maintains protein homeostasis." (abstract, passage verified)
pubmedfull study (doi) - supports: Exercise Regulates Mitochondrial Quality Control: Maintenance and Remodeling of Skeletal M… (Biology 2026)
"As a physiological stress stimulus, exercise can precisely regulate MQC through multiple targets and pathways and restore the homeostasis of skeletal muscles. Exercise activates AMPK-PGC-1α to promote mitochondrial biogenesis, regulates MFN1/2, OPA1, and DRP1 to optimize mitochondrial dynamics, and activates the PINK1/Parkin pathway and receptor-mediated autophagy pathway to enhance mitochondrial autophagy." (abstract, results, passage verified)
pubmedfull study (doi)
Metformin, resveratrol, and NAD boosters promote mitochondrial biogenesis by targeting the AMPK pathway.
"you have these NAD boosters, compounds like resveratrol, at least from a nutrition perspective, or metformin, they're all hitting this sort of AMPK mitochondrial biogenesis pathway." (said at 0:17:39)
Metformin, resveratrol, and NAD-enhancing strategies are well-documented to converge on the interconnected AMPK/SIRT1/PGC-1α signaling network that orchestrates mitochondrial biogenesis. AMPK activation stimulates NAD+ production and SIRT1 deacetylation of PGC-1α, a master transcriptional coactivator of mitochondrial biogenesis, establishing a core positive feedback loop across metabolic regulation.
Sleep disorders can precede and lead to the development of neurodegenerative diseases like Alzheimer's or Parkinson's disease 20 years later.
"And the professor who came to us actually found that these folks actually, all 20 years after sleep issues, they turn into neurodegenerative disorders, so they either get an Alzheimer's or Parkinson's, and the fundamental root cause is mitochondrial imbalance in their brain that triggers these sleep imbalances." (said at 0:20:53)
The claim is overstated. Longitudinal cohort studies demonstrate that specific sleep disorders, most notably isolated rapid eye movement (REM) sleep behavior disorder (iRBD), serve as prodromal manifestations that convert into neurodegenerative alpha-synucleinopathies (such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy) over an extended timeframe, with an average interval of ~14 years and a range spanning up to 29 years. However, this high phenoconversion rate applies specifically to REM sleep behavior disorder rather than generic sleep disorders, does not apply to all sleep issues, and represents early manifestations of ongoing neurodegeneration rather than establishing that sleep disturbance itself causes the subsequent diseases.
- partial: Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially dia… (Sleep medicine 2013) · cited 814x in the literature
"80.8% (21/26) of patients who were initially diagnosed with iRBD eventually developed parkinsonism/dementia (three of the original 29 patients were lost to follow-up). The distribution of diagnoses was as follows: n=13, Parkinson's disease (PD); n=3, dementia with Lewy bodies (DLB); n=1, dementia (unspecified; profound); n=2, multiple system atrophy (MSA); n=2, clinically diagnosed Alzheimer's Disease (AD) with autopsy-confirmed combined AD plus Lewy body disease pathology. Among the 21 iRBD "converters," the mean age (±SD) of iRBD onset was 57.7±7.7 years; mean age (±SD) of parkinsonism/dementia onset was 71.9±6.6 years; and mean interval (±SD) from iRBD onset to parkinsonism/dementia onset was 14.2±6.2 years (range: 5-29 years)." (abstract, results, passage verified)
pubmedfull study (doi)
Exposing muscle cells or other cell types to sodium fluoride causes cellular stress in mitochondria.
"We see that actually if you put some sodium fluoride on muscle cells or any kind of cells, the mitochondria get stressed." (said at 0:22:06)
In vitro and animal experimental models demonstrate that exposure to sodium fluoride induces mitochondrial stress and dysfunction across various cell types. Experimental studies measuring mitochondrial bioenergetics show that sodium fluoride exposure triggers excessive mitochondrial reactive oxygen species (ROS) production, disrupts mitochondrial membrane potential, causes mitochondrial calcium overload, and impairs basal and maximal mitochondrial respiration and ATP production.
- supports: Sirtuin 3-mediated deacetylation of superoxide dismutase 2 ameliorates sodium fluoride-ind… (The Science of the total environment 2024) · cited 16x in the literature
"The findings investigated that NaF increased levels of mitochondrial reactive oxygen species (mtROS) and hindered mitochondrial function, as evidenced by the dissipation of mitochondrial membrane potential, abnormal expression of mitochondrial DNA copy numbers, and mtDNA harm in oocytes." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Fluoride induces spermatocyte apoptosis by IP3R1/MCU-mediated mitochondrial calcium overlo… (Journal of hazardous materials 2025) · cited 30x in the literature
"Mitochondrial stress tests revealed a significant reduction in basal respiration, maximal respiration, and ATP production, suggesting mitochondrial dysfunction following fluoride exposure. Results further indicated that fluoride exposure significantly enhanced ER-mitochondria contacts, mitochondrial Ca 2 + levels, and the expressions of IP3R1, GRP75, VDAC1, and MCU" (abstract, results, passage verified)
pubmedfull study (doi)
High-intensity training and aerobic training have a greater impact on improving mitochondrial health than resistance training.
"Resistance training less so as something like high-intensity training or aerobic training in terms of the impact on mitochondrial health." (said at 0:30:44)
The speaker's claim is supported by exercise physiology literature. Aerobic training and high-intensity interval training are well-established primary stimuli for mitochondrial biogenesis, oxidative enzyme activity, and mitochondrial respiratory capacity in skeletal muscle, primarily through activation of the AMPK-PGC-1α signaling cascade. While resistance training can induce modest mitochondrial improvements (particularly under high-volume or low-load paradigms), its primary adaptive priority and physiological signaling pathways (such as mTORC1) drive myofibrillar protein synthesis, muscle hypertrophy, and ribosome biogenesis rather than substantial mitochondrial remodeling.
Human muscle performance peaks around the third decade of life, after which people lose approximately 10% of muscle strength and mass every 10 years, with loss accelerating beyond 10% per decade in their 60s.
"So when we are in our 30s, we peak in our muscle performance around the third decade of life, and following that, every 10 years we're losing 10% of muscle strength and muscle mass, okay? And that accelerates even bigger than 10% in our 60s." (said at 0:31:43)
The speaker's general trajectory is broadly accurate but conflates the rates of loss between muscle mass and muscle strength/power. Muscle mass and performance typically peak around the third decade of life. However, skeletal muscle mass declines at a slower rate after age 30 (typically estimated at 3% to 8% per decade, or roughly ~15% total between the third and eighth decades in sedentary adults), whereas muscle strength and power decline at higher rates of approximately 10% to 15% per decade. Longitudinal studies confirm that strength loss accelerates further in older age (past age 60–70).
- context: Longitudinal muscle strength changes in older adults: influence of muscle mass, physical a… (The journals of gerontology. Series A, Biological sciences and medical sciences 2001) · cited 928x in the literature
"The rates of decline in isokinetic strength averaged 14% per decade for knee extensors and 16% per decade for knee flexors in men and women. Women demonstrated slower rates of decline in elbow extensors and flexors (2% per decade) than men (12% per decade). Older subjects demonstrated a greater rate of decline in strength." (abstract, results, passage verified)
pubmedfull study (doi) - context: Quadriceps maximal power and optimal shortening velocity in 335 men aged 23-88 years. (European journal of applied physiology 2005) · cited 92x in the literature
"The decline in P(max) across the adult life span (10.7% per decade) was greater than the usually reported decrease in maximal muscle strength. Power decreased already after the fourth decade. Both muscle mass (4.1% decline for LTVest or 3.4% for quadriceps mass per decade) and upsilon(opt) (6.6% decline per decade) contributed to the decrease in power." (abstract, results, passage verified)
pubmedfull study (doi) - context: What is sarcopenia? (The journals of gerontology. Series A, Biological sciences and medical sciences 1995) · cited 604x in the literature
"In sedentary individuals, the main determinant of energy expenditure is fat-free mass, which declines by about 15% between the third and eighth decade of life, contributing to a lower basal metabolic rate in the elderly." (abstract, results, passage verified)
pubmedfull study (doi)
Mitochondria are a primary site where a significant amount of cellular protein synthesis occurs.
"what people forget is that mitochondria is where a lot of protein synthesis is actually happening." (said at 0:32:48)
The claim that mitochondria are where "a lot of protein synthesis is actually happening" or a primary site for cellular protein synthesis is contradicted by cellular biology research. Human mitochondrial DNA encodes only 13 proteins (all subunits of the oxidative phosphorylation system), while the vast majority (approximately 99%) of all mitochondrial proteins—and essentially all non-mitochondrial cellular proteins—are transcribed from nuclear DNA and synthesized by cytosolic ribosomes before being imported into the organelle. Thus, mitochondrial translation accounts for only a minute fraction of overall cellular protein synthesis.
Eating 15% fewer calories has been shown in multiple randomized trials to have a major impact on boosting mitochondrial health.
"So eating 15% less has—we have seen in multiple randomized trials that has a big impact on boosting mitochondrial health." (said at 0:33:40)
While a 6-month randomized controlled trial of 25% caloric restriction (CALERIE Phase 1) found increases in skeletal muscle mitochondrial DNA content and biogenesis gene expression (PMID 17341128), larger and longer-term trials of sustained ~12–15% caloric restriction (CALERIE Phase 2) did not demonstrate a major boost in functional mitochondrial performance. Specifically, 12 months of caloric restriction produced no significant changes in in vivo muscle maximal ATP synthesis rate or coupling efficiency (PMID 27778643), and 24 months of caloric restriction showed no significant difference compared to control in muscle mitochondrial DNA copy number or mutation frequency (PMID 41886216), despite modulating the transcription of genes involved in mitochondrial biogenesis and quality control pathways (PMID 37823711). Claiming that multiple randomized trials demonstrate a major impact on boosting mitochondrial health overstates the human clinical evidence.
- supports: Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. (PLoS medicine 2007) · cited 791x in the literature
"Participants in the CR and CREX groups had increased expression of genes encoding proteins involved in mitochondrial function such as PPARGC1A, TFAM, eNOS, SIRT1, and PARL (all, p < 0.05). In parallel, mitochondrial DNA content increased by 35% +/- 5% in the CR group (p = 0.005)" (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Effects of 12 Months of Caloric Restriction on Muscle Mitochondrial Function in Healthy In… (The Journal of clinical endocrinology and metabolism 2017) · cited 46x in the literature
"In vivo ATPmax and P/O were unaffected by 12 months of CR. Targeted transcriptional profiling showed no effects on pathways involved in mitochondrial biogenesis, function, or oxidative stress... In healthy nonobese humans, CR has no effect on muscle mitochondrial function" (abstract, results and conclusion)
pubmedfull study (doi) - partial: Calorie restriction modulates the transcription of genes related to stress response and lo… (Aging cell 2023) · cited 67x in the literature
"Using linear mixed effect model, we identified protein-coding genes and splicing variants whose expression was significantly changed in the CR group compared to controls, including genes related to proteostasis, circadian rhythm regulation, DNA repair, mitochondrial biogenesis, mRNA processing/splicing, FOXO3 metabolism, apoptosis, and inflammation." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Quadriceps mitochondrial DNA quantity, quality, and gene expression after 2 years of calor… (GeroScience 2026)
"MtDNA copy number was lower in females (p = 0.0005) and declined over time (p = 0.0001), with no statistically significant differences observed for CR versus AL (p = 0.2898)... MtDNA mutation frequency was not statistically different with CR." (abstract, results)
pubmedfull study (doi)
Mitochondria have a preference for utilizing fat as fuel over glucose.
"Their preference for fuel utilization is more fat than glucose." (said at 0:35:49)
The assertion that mitochondria intrinsically prefer utilizing fat over glucose is an oversimplification and overstatement. Mitochondrial substrate utilization is dynamic, highly tissue-specific, and governed by substrate availability, hormonal state, workload, and metabolic flexibility (such as described by the Randle cycle). While certain highly oxidative tissues (such as the adult myocardium and resting skeletal muscle) derive the majority (e.g., 40–70%) of their ATP from fatty acid β-oxidation under normal physiological conditions, other tissues rely predominantly on glucose-derived pyruvate (e.g., brain/neurons, renal medulla, glycolytic muscle fibers) or readily shift preference based on nutritional status (fed vs. fasted state). Mitochondria do not possess a universal, intrinsic preference for fat over glucose across all cell types and conditions.
Urolithin A is a metabolite produced by the gut microbiome from dietary polyphenols and ellagitannins found in foods like pomegranates.
"So what we discovered was that this molecule, urolithin A, is actually not a waste product. It's actually a very potent gut metabolite produced by the gut microbiome that has these immense rejuvenation effects on mitochondria." (said at 0:40:09)
Published research confirms that urolithin A is a postbiotic gut microbial metabolite synthesized by the gut microbiota from dietary precursors, specifically ellagitannins and ellagic acid found in foods such as pomegranates, nuts, and berries. Preclinical and human clinical studies demonstrate that urolithin A stimulates mitophagy (the selective degradation and recycling of damaged mitochondria) and mitochondrial biogenesis, which enhances mitochondrial function and muscle endurance.
- supports: Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle fun… (Nature medicine 2016) · cited 1091x in the literature
"We identified urolithin A (UA) as a first-in-class natural compound that induces mitophagy both in vitro and in vivo following oral consumption." (abstract, results, passage verified)
pubmedfull study (doi) - supports: A mechanistic insight into the biological activities of urolithins as gut microbial metabo… (Phytotherapy research : PTR 2022) · cited 54x in the literature
"Urolithins are the gut metabolites produced from ellagitannin-rich foods such as pomegranates, tea, walnuts, as well as strawberries, raspberries, blackberries, and cloudberries." (abstract, background, passage verified)
pubmedfull study (doi) - supports: The microbiome-mitochondria axis: the context-dependent role of urolithin A in aging and c… (Molecular biology reports 2026)
"Urolithin A (UA) is a gut microbiota-derived metabolite formed from dietary ellagitannins and ellagic acid. It has drawn sustained interest because it can influence mitochondrial quality control" (abstract, background, passage verified)
pubmedfull study (doi)
Approximately 40% of sampled French and Italian individuals naturally produce detectable urolithin A from their diet, compared to 10% in the US and Canada and 5% in India.
"So if you go to the French and the Italians, you find out of 100 people you sample, 40% will make from the diet naturally, real-world level, they will have some levels of urolithin A in their bloodstream. You go to the US and Canada, that number drops to 10%... You go to my origin country, which is India, where every kid growing up in their first year is given antibiotics for everything, the incidence drops to 5%." (said at 0:40:27)
No published record matching the claim that approximately 40% of French and Italian individuals, 10% of individuals in the US and Canada, and 5% of individuals in India naturally produce detectable urolithin A from their diet was located; this does not prove the claim false. While human nutritional studies show that the gut microbiota's ability to metabolize dietary ellagitannins into urolithins varies substantially between individuals (with general producer phenotypes typically estimated at 30% to 40% in healthy cohorts), standardized multi-country epidemiological datasets validating these specific geographic percentages and attributing the lower rate in India to early-life antibiotic use have not been published.
Placebo-controlled randomized trials show that urolithin A supplementation leads to approximately a 10% to 12% improvement in muscle strength, a 10% increase in VO2 levels, and lower inflammation without changes in exercise or diet.
"Mostly the trials we've run in in placebo-controlled randomized trials, we see in the absence of exercise, in the absence of changing their diets, you get about a 10, 12% improvement in strength, you get about a 10% improvement in VO2 levels. So this aerobic endurance we talked about, and you also get lower inflammation." (said at 0:41:30)
Randomized, placebo-controlled clinical trials support the claim. In middle-aged adults (40–65 years old), four months of daily Urolithin A (Mitopure) supplementation without exercise or dietary changes led to a statistically significant ~12% improvement in muscle strength, improvements in aerobic endurance/peak VO2, and significant reductions in C-reactive protein (CRP), indicating reduced systemic inflammation. Similar reductions in inflammatory markers (CRP) and improvements in muscle endurance were also demonstrated in a separate 4-month randomized controlled trial in older adults.
- supports: Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Olde… (JAMA network open 2022) · cited 197x in the literature
"Plasma levels of several acylcarnitines, ceramides, and C-reactive protein were decreased by urolithin A, compared with placebo, at 4 months" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondria… (Cell reports. Medicine 2022) · cited 247x in the literature
"The data show significant improvements in muscle strength (∼12%) with intake of Urolithin A. We observe clinically meaningful improvements with Urolithin A on aerobic endurance (peak oxygen oxygen consumption [VO 2 ]) and physical performance (6 min walk test) but do not notice a significant improvement on peak power output (primary endpoint). Levels of plasma acylcarnitines and C-reactive proteins are significantly lower with Urolithin A, indicating higher mitochondrial efficiency and reduced inflammation." (abstract, results, passage verified)
pubmedfull study (doi)
In clinical studies on sedentary older adults, oral dosing of 500 mg to 1 g of urolithin A increases PGC-1 alpha and decreases damaged mitochondrial DNA at 1 month, improves peak VO2 at 2 months, and increases muscle strength after 4 months.
"The first studies I did was I started giving, you know, increasing doses of this molecule to older adults who are sedentary, and I found a sweet spot around the 500 milligram to a gram dosing of this molecule where a month in, no big physiological effects, but if I went in and took blood and biopsies, I could see the damaged mitochondria turn and become into healthier mitochondria. There was more PGC-1 alpha, there was less damaged mitochondrial DNA. Two months into supplementation is where I pick up things like physiological changes. So peak VO2 is improved... And then longer term, 4 months up, we start seeing these real long-term benefits that I mentioned about, which is improvement in strength." (said at 0:42:34)
The speaker conflates findings and timelines across multiple distinct clinical trials conducted by their research team. In a 4-week trial in sedentary older adults (500 mg and 1,000 mg/day), urolithin A was found to modulate skeletal muscle mitochondrial gene expression and plasma biomarkers without functional changes. In a subsequent 4-month trial in older adults (65–90 years), supplementation improved muscle endurance at 2 months, but primary endpoints (6-minute walk distance and maximal ATP production) did not show statistically significant differences versus placebo at 4 months. Improvements in peak VO2 and muscle strength (~12%) were actually demonstrated at 4 months in a separate randomized trial of middle-aged adults (40–65 years), rather than at 2 months or exclusively in older adults.
- supports: The mitophagy activator urolithin A is safe and induces a molecular signature of improved … (Nature metabolism 2019) · cited 568x in the literature
"UA was bioavailable in plasma at all doses tested, and 4 weeks of treatment with UA at doses of 500 mg and 1,000 mg modulated plasma acylcarnitines and skeletal muscle mitochondrial gene expression in elderly individuals (secondary outcomes)." (abstract, results, passage verified)
pubmedfull study (doi) - partial: Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Olde… (JAMA network open 2022) · cited 197x in the literature
"Urolithin A, compared with placebo, significantly improved muscle endurance (ie, increase in the number of muscle contractions until fatigue from baseline) in the FDI and TA at 2 months... Although the improvements in the 6-minute walk distance and maximal ATP production in the hand muscle were not significant in the urolithin A group vs the placebo group, long-term urolithin A supplementation was beneficial for muscle endurance and plasma biomarkers" (abstract, results and conclusions)
pubmedfull study (doi) - partial: Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondria… (Cell reports. Medicine 2022) · cited 247x in the literature
"We present results from a randomized, placebo-controlled trial in middle-aged adults where we administer a postbiotic compound Urolithin A (Mitopure), a known mitophagy activator, at two doses for 4 months (NCT03464500). The data show significant improvements in muscle strength (~12%) with intake of Urolithin A. We observe clinically meaningful improvements with Urolithin A on aerobic endurance (peak oxygen oxygen consumption [VO 2 ]) and physical performance (6 min walk test) but do not notice a significant improvement on peak power output (primary endpoint)." (abstract, results, passage verified)
pubmedfull study (doi)
Clinical trials of urolithin A across sedentary older adults, overweight individuals, and elite athletes consistently demonstrate reductions in C-reactive protein, interleukin-1 beta, and TNF-alpha alongside improved mitochondrial health.
"The early trials we did, as I mentioned, whether it was the older adults, you know, sitting on their couch potato, not getting to move, or the overweight folks, or even the elite athletes, the hallmarks—whenever we would see improved mitochondrial health, in the background we would always see lowering of C-reactive protein, we would always see lowering of interleukin-1 beta or TNF-alpha." (said at 0:47:09)
Randomized controlled trials evaluating urolithin A in humans (including older adults and trained endurance athletes) have shown preliminary signals of mitochondrial modulation and proteomic downregulation of inflammatory pathways. However, claiming that trials across sedentary older adults, overweight individuals, and elite athletes 'consistently demonstrate' or 'always' show significant reductions in C-reactive protein (CRP), interleukin-1 beta (IL-1β), and TNF-α overstates the published evidence. A systematic review of human trials notes that clinical evidence remains preliminary across small cohorts (n = 236 across five trials), with mitochondrial and inflammatory biomarkers showing heterogeneous, exploratory outcomes rather than established, consistent efficacy.
- partial: Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and… (Sports medicine (Auckland, N.Z.) 2025) · cited 7x in the literature
"Proteomic screening of skeletal muscle biopsies revealed UA upregulated pathways associated with mitochondria, while downregulating inflammatory pathways. While not statistically significant, UA led to a medium effect for increased markers of mitophagy (d = - 0.74), without changes in mitochondrial function." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized… (Frontiers in nutrition 2026)
"Five randomized controlled trials ( n = 236) were included... Non-6MWT outcomes - muscle strength, endurance, aerobic capacity, and biochemical or mitochondrial biomarkers - were heterogeneous across populations, doses, and assessment modalities, were not quantitatively pooled, and are reported as exploratory signals rather than reproducible effects." (abstract, results)
pubmedfull study (doi)
A clinical trial administering urolithin A for one month to healthy 40- to 50-year-olds profiling over 80 immune populations showed an increase in age-declining immune cells (such as T cells and NK cells) containing higher numbers of mitochondria and enhanced pathogen-killing capacity.
"And he said, 'Well, let's do a trial where we give this molecule for a month to healthy 40, 50-year-olds and we look at every single immune cell in the body, at the impact it's causing and the mitochondria in it.'... What we actually now find with supplementation is that a lot of these immune cells that are declining with aging, they come back with Mitopure supplementation. And when they come back, they have more mitochondria... And these immune cells are more wired to fight infection. So if you throw an infection on them, they engulf it and kill it much faster." (said at 0:47:42)
A double-blind, randomized, placebo-controlled clinical trial in 50 healthy middle-aged adults evaluated 4 weeks (1 month) of oral urolithin A (1,000 mg/day) supplementation. The trial found that urolithin A supplementation expanded naive-like CD8+ T cells and peripheral NK cell subsets, augmented mitochondrial biogenesis in CD8+ T cells, improved T-cell cytokine activation, and enhanced bacterial phagocytosis (uptake) in monocytes.
In animal models of heart failure, Mitopure (Urolithin A) supplementation reversed cardiac damage by improving mitochondrial health.
"we went into models of heart failure, acute and chronic, and we found that giving Mitopure supplementation in these models reversed a lot of this cardiac damage by improving mitochondrial health." (said at 1:29:16)
Preclinical studies in animal models of heart failure and cardiac aging support the claim. Research shows that Urolithin A (Mitopure) supplementation reduces cardiac dysfunction, hypertrophy, and fibrosis while restoring mitochondrial ultrastructure, respiration, and mitophagy. Because these findings are established in animal and cellular models, the certainty of evidence for clinical human efficacy in heart failure remains very low.
- supports: Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically … (iScience 2025) · cited 26x in the literature
"Preclinically, the post-biotic and mitophagy activator, urolithin A (UA), reduced both systolic and diastolic cardiac dysfunction in models of natural aging and heart failure. At a cellular level, this was associated with a recovery of mitochondrial ultrastructural defects and mitophagy." (abstract, passage verified)
pubmedfull study (doi) - supports: Urolithin A activates mitophagy via the AMPK-mTOR axis and modulates the gut-ceramide axis… (Experimental & molecular medicine 2026) · cited 1x in the literature
"In vitro and in vivo experiments, together with multi-omics analyses, showed that UA alleviated diastolic dysfunction, cardiac hypertrophy, and fibrosis in HFpEF mice. These effects were accompanied by restoration of mitochondrial ultrastructure and enhanced mitochondrial respiration and glycolytic capacity." (abstract, passage verified)
pubmedfull study (doi)
Cardiac biopsies from patients who have heart failure or died of cardiac degeneration show poor mitochondrial health as a hallmark signature.
"they actually looked at cardiac biopsies of people who had heart failure or had died of heart degeneration and with the aging process. And again, the signature, the hallmark signature they picked up in the heart was poor mitochondrial health." (said at 1:29:16)
Published clinical and histopathological studies evaluating human myocardial biopsies confirm that mitochondrial abnormalities and dysfunction are hallmark signatures of cardiac degeneration, aging, and heart failure. In patients undergoing endomyocardial biopsies for heart failure, structural and functional mitochondrial impairments (such as cristae disorganization and membrane disruption) are prominent features that correlate strongly with disease severity, impaired reverse remodeling, and adverse cardiovascular outcomes.
In clinical trials, Mitopure supplementation reduces plasma levels of ceramides in humans.
"And what we see is actually in all our trials, plasma levels of ceramides are going down." (said at 1:30:00)
Randomized controlled trials evaluating urolithin A (Mitopure) supplementation in older adults have demonstrated reductions in circulating plasma ceramide levels. In a double-blind, placebo-controlled clinical trial (PMID 35050355), four months of oral urolithin A supplementation significantly decreased plasma levels of several ceramides, acylcarnitines, and C-reactive protein compared with placebo. Subsequent analyses and human trials (PMID 40034121) similarly report that four months of urolithin A supplementation reduces cardiovascular-risk-associated plasma ceramides.
- supports: Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Olde… (JAMA network open 2022) · cited 197x in the literature
"Plasma levels of several acylcarnitines, ceramides, and C-reactive protein were decreased by urolithin A, compared with placebo, at 4 months (baseline vs 4 mo: urolithin A, 2.14 [2.15] vs 2.07 [1.46]; placebo, 2.17 [2.52] vs 2.65 [1.86])." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically … (iScience 2025) · cited 26x in the literature
"In humans, UA supplementation for 4 months in healthy older adults significantly reduced plasma ceramides clinically validated to predict CVD risks." (abstract, results, passage verified)
pubmedfull study (doi)
The Mayo Clinic has a clinical ceramide score that predicts cardiovascular disease prognosis.
"there's the Mayo Clinic that has now a score of ceramides that allows you to predict the prognosis of cardiovascular health." (said at 1:30:30)
Mayo Clinic researchers developed and clinically implemented a plasma ceramide risk score (evaluating circulating ceramides such as Cer(16:0), Cer(18:0), and Cer(24:1) along with their ratios to Cer(24:0)) to assess cardiovascular risk. Prospective cohort studies have demonstrated that higher ceramide risk scores independently predict major adverse cardiovascular events (including myocardial infarction, stroke, and cardiovascular mortality) even after adjusting for standard lipid panels and traditional cardiovascular risk factors.
- supports: Plasma Ceramides. (Arteriosclerosis, thrombosis, and vascular biology 2018) · cited 235x in the literature
"The fully adjusted per SD hazard ratios (95% confidence interval) were 1.50 (1.16-1.93) for Cer(16:0), 1.42 (1.11-1.83) for Cer(18:0), 1.43 (1.08-1.89) for Cer(24:1), and 1.58 (1.22-2.04) for the ceramide risk score. Conclusions- Elevated plasma concentrations of ceramides are independently associated with major adverse cardiovascular events in patients with and without coronary artery disease." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard r… (Clinica chimica acta; international journal of clinical chemistry 2020) · cited 54x in the literature
"Their independent prognostic value for future cardiovascular outcomes over and above LDL cholesterol and other traditional risk factors have consistently been shown in numerous clinical studies. Thus, ceramide testing with a mass spectrometer offers a simple, reproducible and cost-effective blood test for risk stratification in atherosclerotic cardiovascular diseases." (abstract, passage verified)
pubmedfull study (doi)
Mitopure (Urolithin A) supplementation improves VO2 max in humans.
"But we do know things like VO2 max improve with Mitopure, which is also cardiovascular health." (said at 1:30:50)
A double-blind, randomized, placebo-controlled trial evaluating Urolithin A (Mitopure) supplementation in middle-aged adults demonstrated improvements in aerobic endurance measured by peak oxygen consumption (peak VO2) and 6-minute walk distance, alongside improvements in muscle strength and mitochondrial biomarkers. In trained male distance runners, supplementation also led to significant within-group increases in VO2 max, although between-group differences compared to placebo during altitude training camp did not reach statistical significance.
- supports: Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondria… (Cell reports. Medicine 2022) · cited 247x in the literature
"We present results from a randomized, placebo-controlled trial in middle-aged adults where we administer a postbiotic compound Urolithin A (Mitopure), a known mitophagy activator, at two doses for 4 months (NCT03464500)... We observe clinically meaningful improvements with Urolithin A on aerobic endurance (peak oxygen oxygen consumption [VO 2 ]) and physical performance (6 min walk test)" (abstract, results, passage verified)
pubmedfull study (doi) - context: Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and… (Sports medicine (Auckland, N.Z.) 2025) · cited 7x in the literature
"Although there was no statistically significant time × treatment interaction for aerobic capacity (p = 0.138), UA supplementation showed a large within-group increase in V ˙ O 2max (5.4 ± 0.9%, 66.4 ± 0.8 to 70.0 ± 1.0 mL·kg -1 ·min -1 , p = 0.009, d = - 0.83), with a smaller increase in the PL group" (abstract, results, passage verified)
pubmedfull study (doi)
Skin fibroblasts and keratinocytes accumulate mitochondrial damage with aging.
"skin cells in the fibroblasts or the keratinocytes—these are the two main cells in the epidermis and the dermis—they have lots of mitochondria. And over aging, over time of adult healthspan, they get damaged in much the same way as muscle and brain cells do." (said at 1:35:07)
Skin fibroblasts (in the dermis) and keratinocytes (in the epidermis) accumulate mitochondrial damage and dysfunction over chronological aging and photoaging. Published literature demonstrates that advancing age and cumulative environmental stressors lead to mitochondrial DNA (mtDNA) damage, impaired oxidative phosphorylation, elevated reactive oxygen species (ROS), and defective mitophagy in cutaneous cells, mirroring aging pathways observed in high-energy metabolic tissues.
- supports: Determination of the Action Spectrum of UVR-Induced Mitochondrial DNA Damage in Human Skin… (The Journal of investigative dermatology 2015) · cited 15x in the literature
"Although mitochondrial DNA (mtDNA) damage has been shown to be a reliable and sensitive biomarker of UVR exposure in human skin, its wavelength dependency is unknown. The current study solves this problem by determining the action spectrum of UVR-induced mtDNA damage in human skin. Human neonatal dermal fibroblasts and primary human adult keratinocyte cells were irradiated with increasing doses of UVR." (abstract, passage verified)
pubmedfull study (doi) - supports: The Mitochondrial Blueprint of Skin Aging: From Damage Signals to Dermatologic Interventio… (Aging and disease 2026)
"In cutaneous tissues, mitochondrial integrity sustains fibroblast-driven collagen synthesis, keratinocyte proliferation, melanocyte homeostasis, and efficient wound repair. With advancing age and cumulative ultraviolet exposure, mitochondria accumulate hallmark defects. Mitochondrial DNA mutations and deletions, impaired oxidative phosphorylation, excessive reactive oxygen species production, diminished mitophagy and biogenesis, disrupted fission-fusion dynamics, NAD⁺ decline, and sirtuin dysregulation all converge to undermine energy metabolism, amplify inflammatory signaling, and accelerate fibroblast senescence, extracellular matrix degradation, pigmentary changes, and delayed wound healing." (abstract, passage verified)
pubmedfull study (doi)
In randomized trials, topical Mitopure improved mitochondrial health in skin biopsies and decreased levels of collagen-degrading matrix metalloproteinases (MMPs).
"we made these topical formulations with Mitopure and applied it in randomized trials in middle-aged, older-age volunteers. And lo and behold, when we did the skin biopsies, the mitochondrial health started turning... And what we saw in these trials was that MMP levels were going down." (said at 1:35:45)
No published record matching randomized clinical trials of topical Mitopure (urolithin A) assessing mitochondrial health and matrix metalloproteinase (MMP) levels in human skin biopsies was located; this does not prove the claim false. While in vitro laboratory studies in cultured human dermal fibroblasts have demonstrated that urolithin A can induce mitophagy and downregulate MMP-1 expression, peer-reviewed human randomized trial data evaluating topical formulations and skin biopsy outcomes remain unpublished in the medical literature.
Matrix metalloproteinases (MMPs) degrade collagen and increase significantly with aging.
"And there are enzymes called matrix metalloproteinases, MMPs, that degrade collagen that just shoot up with aging." (said at 1:36:00)
Matrix metalloproteinases (MMPs), particularly collagenases such as MMP-1, are enzymes responsible for degrading collagen fibrils in human extracellular matrix. Extensive human skin tissue and cell culture studies confirm that MMP expression and activity increase significantly with chronological aging and photoaging, driving age-related collagen fragmentation and loss.
Statins deplete the electron transport chain and cause coenzyme Q10 deficiency.
"At a higher level, they are mitochondrial toxins, and they deplete the electron transport chain, and CoQ10 deficiency happens." (said at 1:48:38)
Statins inhibit HMG-CoA reductase, an upstream enzyme in the mevalonate pathway required for the biosynthesis of coenzyme Q10 (CoQ10/ubiquinone), an essential electron carrier in the mitochondrial electron transport chain. A systematic review and meta-analysis of randomized placebo-controlled trials confirmed that statin therapy significantly reduces circulating CoQ10 concentrations across all statin classes (WMD: -0.44 μmol/L, 95% CI: -0.52 to -0.37). In addition, in vitro and preclinical studies demonstrate that higher concentrations of statins exhibit mitochondrial toxicity by inhibiting electron transport chain complexes (such as Complex I and III) and impairing oxidative phosphorylation, mechanisms implicated in statin-induced myopathy.
- supports: Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analys… (Pharmacological research 2015) · cited 193x in the literature
"The data from 8 placebo-controlled treatment arms suggested a significant reduction in plasma CoQ10 concentrations following treatment with statins (WMD: -0.44 μmol/L, 95%CI: -0.52, -0.37, p<0.001). The pooled effect size was robust and remained significant in the leave-one-out sensitivity analysis." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The Role of Mitochondria in Statin-Induced Myopathy. (Drug safety 2024) · cited 18x in the literature
"The exact aetiology of statin-induced myopathy remains to be elucidated, although impaired mitochondrial function is thought to be an important underlying cause. This may result from or be the consequence of several factors including statin-induced inhibition of coenzyme Q 10 (CoQ 10 ) biosynthesis, impaired Ca 2+ signalling and modified reactive oxygen species (ROS) generation." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Atorvastatin Induces Bioenergetic Impairment and Oxidative Stress Through Reverse Electron… (Antioxidants (Basel, Switzerland) 2025) · cited 3x in the literature
"However, the use of statins is associated with several side effects, likely due to the depletion of Coenzyme Q 10 (CoQ 10 ), a key component of the mitochondrial electron transport chain and a membrane antioxidant. In our study, we present evidence of the cytotoxic effects of Atorvastatin on human dermal fibroblasts in terms of oxidative stress and mitochondrial impairment... Moreover, our data suggest that the mechanism for Atorvastatin off-target effects at high concentrations involves the inhibition of respiratory complexes I and III, leading to reverse electron transport and ROS production by Complex I." (abstract, results, passage verified)
pubmedfull study (doi)
Coenzyme Q10 has low oral bioavailability.
"CoQ10 is not also a very highly bioavailable compound when taken orally." (said at 1:50:29)
Coenzyme Q10 (CoQ10 / ubiquinone) is well established in pharmacokinetic research to possess poor oral bioavailability. Due to its high molecular weight (863 g/mol), strong lipophilicity/hydrophobicity, and poor aqueous solubility, intestinal absorption of standard oral CoQ10 is slow and limited, prompting extensive pharmaceutical development into specialized delivery systems (such as solubilized, lipid-based, or nanoemulsion formulations) to improve systemic absorption.
- supports: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. (Free radical research 2006) · cited 546x in the literature
"Because of its hydrophobicity and large molecular weight, absorption of dietary CoQ10 is slow and limited." (abstract, passage verified)
pubmedfull study (doi) - supports: Strategies for oral delivery and mitochondrial targeting of CoQ10. (Drug delivery 2016) · cited 87x in the literature
"However, CoQ10 has low oral bioavailability due to its lipophilic nature, large molecular weight, regional differences in its gastrointestinal permeability and involvement of multitransporters." (abstract, passage verified)
pubmedfull study (doi) - supports: Coenzyme Q 10 : Novel Formulations and Medical Trends. (International journal of molecular sciences 2020) · cited 75x in the literature
"Despite its multiple therapeutic applications, CoQ 10 is not commonly prescribed as a drug because of its low oral bioavailability, which compromises its efficacy." (abstract, passage verified)
pubmedfull study (doi)
GLP-1 receptor agonist medications cause a 20% to 30% loss of muscle mass.
"there's this buzz with the GLP-1 that, you know, with the GLP-1 story, that you lose 20, 30% muscle." (said at 1:52:29)
The claim confuses the composition of total weight lost with the proportion of overall muscle mass lost. In clinical trials and meta-analyses of GLP-1 receptor agonists, lean or muscle mass accounts for approximately 20% to 30% of the total weight lost (a standard proportion seen during calorie restriction and weight reduction). However, patients do not lose 20% to 30% of their total body muscle mass; baseline lean mass decreases by only around 3% to 5% (or ~1.7 to 5.4 kg), and because fat mass decreases much more substantially, lean mass as a proportion of total body weight actually increases.
Vitamin D has beneficial effects on mitochondrial function and immune cells.
"You know, vitamin D—we didn't talk about that, but also has some great effects on mitochondria and immune cells." (said at 1:57:11)
Published molecular, preclinical, and human experimental studies demonstrate that vitamin D and its active metabolite calcitriol (1,25-dihydroxyvitamin D) exert significant regulatory and protective effects on both mitochondrial function and immune cells. Vitamin D influences mitochondrial energy production, dynamics (fission-fusion), and membrane potential while modulating innate and adaptive immune cell signaling, metabolic reprogramming, and cytokine production.
- supports: Vitamin D Supplementation Improves Mitochondrial Function and Reduces Inflammation in Plac… (Frontiers in endocrinology 2022) · cited 37x in the literature
"Vitamin D (VitD) is a major player in calcium uptake and was shown to modulate mitochondrial respiration and the immune/inflammation system." (abstract, introduction, passage verified)
pubmedfull study (doi) - supports: Nongenomic Activities of Vitamin D. (Nutrients 2022) · cited 93x in the literature
"Vitamin D was also found to stimulate a release of secondary massagers and modulate several intracellular processes-including cell cycle, proliferation, or immune responses-through wingless (WNT), sonic hedgehog (SSH), STAT1-3, or NF-kappaB pathways... Vitamin D also directly and indirectly influences mitochondrial function, including fusion-fission, energy production, mitochondrial membrane potential, activity of ion channels, and apoptosis." (abstract, passage verified)
pubmedfull study (doi) - supports: Vitamin D as a multisystem regulatory hormone: Molecular pathways, physiological integrati… (The Journal of steroid biochemistry and molecular biology 2026) · cited 3x in the literature
"Emerging experimental evidence highlights the regulatory role of this vitamin across multiple organ systems and signaling pathways involved in endocrine, musculoskeletal, immune, metabolic, and neurobiological functions... By positioning vitamin D as a regulator of interconnected molecular networks, this review provides a systems-level framework linking vitamin D signaling to metabolic efficiency, mitochondrial function, and musculoskeletal health." (abstract, passage verified)
pubmedfull study (doi)
Studies demonstrate that antibiotics act as mitochondrial stressors.
"There's enough studies showing they're mitochondrial stressors. Now, I think it really depends on the duration of usage, the dose, and certain classes of antibiotics are probably worse off than the others." (said at 1:57:42)
The statement that studies demonstrate antibiotics act as mitochondrial stressors—with effects depending on duration, dose, and antibiotic class—is supported by published literature. Due to the shared evolutionary origin between mitochondria and bacteria, several major classes of antibiotics (such as aminoglycosides, fluoroquinolones, macrolides, and oxazolidinones like linezolid) can inhibit mitochondrial protein synthesis or electron transport chain activity. A landmark study demonstrated that clinically relevant concentrations of bactericidal antibiotics (quinolones, aminoglycosides, and beta-lactams) induce mitochondrial dysfunction, overproduction of reactive oxygen species (ROS), and oxidative damage in mammalian cells and animal models. Furthermore, clinical investigations in humans show that prolonged exposure to specific agents, such as linezolid, induces progressive mitochondrial respiratory impairment in a duration-dependent manner.
Scientific evidence demonstrates beneficial effects of sauna use on mitochondrial health.
"There's a lot of good evidence in sauna for mitochondria." (said at 1:57:54)
The speaker claims there is 'a lot of good evidence in sauna for mitochondria.' While experimental heat therapy (such as localized diathermy or passive heating) and preclinical animal models suggest heat stress can induce mitochondrial adaptations and increase skeletal muscle mitochondrial respiratory capacity, the human evidence is very limited and in its infancy rather than abundant or definitive. Direct human trials on sauna bathing specifically measuring mitochondrial biogenesis or function are scarce, and studies on passive heating show mixed or selective outcomes (e.g., improved respiratory capacity without changes in fatty acid oxidation or citrate synthase activity).
- partial: Localized Heat Therapy Improves Mitochondrial Respiratory Capacity but Not Fatty Acid Oxid… (International journal of molecular sciences 2022) · cited 16x in the literature
"The primary finding of this work was that heat therapy and exercise training significantly improved mitochondrial respiratory capacity by 24.8 ± 6.2% and 27.9 ± 8.7%, respectively (p < 0.05). Fatty acid oxidation and citrate synthase activity were also increased following exercise training by 29.5 ± 6.8% and 19.0 ± 7.4%, respectively (p < 0.05). However, contrary to our hypothesis, heat therapy did not increase fatty acid oxidation or citrate synthase activity." (abstract, results, passage verified)
pubmedfull study (doi) - context: Passive heat stress induces mitochondrial adaptations in skeletal muscle. (International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2023) · cited 16x in the literature
"Passive heating (i.e., application of heat in the absence of muscle contractions) is one potential intervention which has been shown to increase mitochondrial enzyme content and activity, and to improve mitochondrial respiration. Associated with increases in mitochondrial content and/or function, passive heating can also improve insulin sensitivity in the context of type II diabetes and preserve muscle mass in the face of limb disuse. This area of research remains in its infancy, with many questions yet to be answered about how to maximize the benefits of passive heating and elucidate the mechanisms by which heat stress affects muscle mitochondria." (abstract, conclusions, passage verified)
pubmedfull study (doi)
Research shows that living in colder environments is better for mitochondrial function than living in warmer or tropical climates.
"There's a great research coming out from one of our collaborators who co-discovered Urolithin with us, where he's seeing that living in cold rooms or colder areas is better for your mitochondria than living in hot climates and tropical areas." (said at 1:58:47)
No published record matching the claim that living in colder environments or rooms is better for mitochondrial function than living in warmer or tropical climates was located; this does not prove the claim false. While acute cold exposure is known to stimulate brown adipose tissue thermogenesis and mitochondrial uncoupling in laboratory models, broad epidemiological or comparative physiological trials establishing superior mitochondrial function from residing in cold versus tropical climates have not been published.
Fact-checked episodes
Publications